Connor Clark & Lunn Investment Management Ltd. Raises Stock Position in Accuray Incorporated (NASDAQ:ARAY)

Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Accuray Incorporated (NASDAQ:ARAY) by 2.0% in the 4th quarter, HoldingsChannel reports. The firm owned 283,280 shares of the medical equipment provider’s stock after purchasing an additional 5,421 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Accuray were worth $561,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Caprock Group LLC acquired a new position in shares of Accuray during the third quarter worth $36,000. Intech Investment Management LLC acquired a new position in Accuray in the third quarter valued at $41,000. Thrivent Financial for Lutherans acquired a new stake in Accuray during the 3rd quarter worth approximately $57,000. SG Americas Securities LLC increased its stake in Accuray by 37.4% in the 4th quarter. SG Americas Securities LLC now owns 45,079 shares of the medical equipment provider’s stock valued at $89,000 after buying an additional 12,259 shares during the period. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Accuray during the third quarter worth about $231,000. Hedge funds and other institutional investors own 64.08% of the company’s stock.

Accuray Stock Performance

Shares of ARAY stock opened at $1.86 on Friday. The company has a debt-to-equity ratio of 3.51, a quick ratio of 0.88 and a current ratio of 1.62. The stock has a market cap of $191.27 million, a PE ratio of -37.20 and a beta of 1.46. Accuray Incorporated has a 1 year low of $1.40 and a 1 year high of $2.95. The stock has a fifty day moving average price of $2.12 and a 200 day moving average price of $1.99.

Accuray (NASDAQ:ARAY) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.03. Accuray had a negative net margin of 0.96% and a negative return on equity of 9.75%. Sell-side analysts forecast that Accuray Incorporated will post 0.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded shares of Accuray from a “hold” rating to a “buy” rating in a report on Saturday, March 15th.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.